{'fraction_non_alphanumeric': 0.02271062271062271, 'fraction_numerical': 0.014652014652014652, 'mean_word_length': 5.26605504587156, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 1, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
P.152 Efficacy of Dorsal Root Ganglion Stimulation for Post Surgical Neuropathic Pain

Background: The dorsal root ganglion (DRG) has been established as an important structure in the development and modulation of chonic neuropathic pain and has demonstrated superiority over spinal cord stimulation in the management of challenging neuropathic pain conditions, including complex regional pain syndrome and chronic post-spine surgery neuropathic pain. DRG has only been available in Canada for patient application since January 2020. The St Pauls Hospital Neuromodulation Program was one of the first Canadian centers to offer this procedure. Methods: We reviewed our early experience with DRG therapy in 10 patients. Patient-reported outcome measures were collected pre-trial, post-trial, and post-device implantation, to determine the efficacy of DRG. We hypothesized that DRG stimulation would demonstrate a meaningful change in PROMIS-29 domains and at least 50% improvement in pain intensity at 8 wks. Results: All patients demonstrated a > 5 point change in T scores in PROMIS-29 domains suggesting a meaningful benefit. Patients also demonstrated a percentage pain improvement at 8 wks of 64 % based on a numerical rating scale. No major complications were observed. Conclusions: DRG stimulation is a safe and effective treatment option for neuropathic pain.